Neuroprotective Effects of Combination Therapy with Tirilazad and Magnesium in Rats Subjected to Reversible Focal Cerebral Ischemia

Abstract

Combined therapy with antagonists of excitatory amino acids and free radicals provides better neuroprotection from the effects of transient focal ischemia than does therapy with either antagonist alone. In contrast to many experimental agents, tirilazad and magnesium offer the advantage of being licensed for clinical use. This drug combination could be of great benefit when administered before temporary artery occlusion in patients undergoing cerebrovascular surgery.